Form 4: Cocrystal Pharma Director Boosts Stake with Share Purchases

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 4,000 shares of common stock through indirect ownership.

Summary

• Phillip Frost, MD, a Director and 10% owner of Cocrystal Pharma, Inc. (COCP), purchased additional common stock.
• On November 26, 2025, 1,500 shares were acquired at $1.00 per share.
• On the same date, an additional 2,500 shares were acquired at $0.99 per share.
• These purchases were made indirectly through Frost Gamma Investments Trust.
• Following these transactions, Frost Gamma Investments Trust beneficially owns 1,703,551 shares of common stock.
• Phillip Frost also directly owns 27,100 shares, which include shares issuable upon vesting of restricted stock units.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The insider buying by a significant shareholder and director, Phillip Frost, indicates strong confidence in the company's valuation and future prospects. This is generally viewed positively by the market.

Positives

• A Director and 10% owner, Phillip Frost, increased his stake in Cocrystal Pharma, Inc. by purchasing 4,000 shares.
• The purchases were made at prices of $1.00 and $0.99 per share, indicating management's confidence at these price levels.
• The transactions were executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein.
• Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein.

Related Party Transactions

• The shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D. is the trustee, and Frost Gamma L.P. is the sole beneficiary. Dr. Frost is one of two limited partners of Frost Gamma L.P., and the general partner is Frost Gamma, Inc., whose sole stockholder is Frost-Nevada Corporation, with Dr. Frost as its sole stockholder.

Stakeholder Impact

• Shareholders may view the insider purchases as a positive signal of management's belief in the company's value and future performance, potentially increasing investor confidence.

Key Dates

Recommendation

The insider buying by a significant director and 10% owner, Phillip Frost, is a positive signal, indicating confidence in the company's current valuation and future. While this action alone doesn't warrant a 'buy' without broader financial analysis, it suggests that existing shareholders should 'hold' their positions, as a key insider is increasing their stake. It mitigates potential negative sentiment and suggests stability.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Buying, Form 4, Stock Purchase, Director, 10% Owner, Beneficial Ownership, Pharmaceuticals